Vertex Pharmaceuticals logged a -1.2% change during today's afternoon session, and is now trading at a price of $356.18 per share. On average, analysts give it a target price of $387.38.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). The large-cap company is based in the United States.
Make Sure to Consider the Following Before Buying Vertex Pharmaceuticals:
-
Vertex Pharmaceuticals has moved 21.0% over the last year.
-
VRTX has a forward P/E ratio of 22.0 based on its EPS guidance of 16.22.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 52.6%.
-
The company has a price to earnings growth (PEG) ratio of 2.42.
-
Its Price to Book (P/B) ratio is 5.94
Vertex Pharmaceuticals Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-10 | 4,129,900 | -204,700 | 4,334,600 | 50.59 |
| 2022-02-09 | 2,643,500 | -235,000 | 2,878,500 | -18.07 |
| 2021-02-11 | 3,253,500 | -259,800 | 3,513,300 | 113.61 |
| 2020-02-13 | 1,569,300 | -75,400 | 1,644,700 | 20.43 |
| 2019-02-13 | 1,270,286 | -95,449 | 1,365,735 | 23.67 |
| 2018-02-15 | 844,942 | -259,421 | 1,104,363 |
Vertex Pharmaceuticals's free cash flows have a decent average of $2.47 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 4111805845.3%. The compounded average growth rate over this period is 0.0%.
